Gemini Therapeutics (Nasdaq: GMTX), a US-based clinical stage ophthalmic company focused on age-related macular degeneration (AMD), has announced a Phase 2a treatment (“ReGAtta” study) and… Read More »Gemini Therapeutics (Cambridge, MA) expect to announce Phase 2a results in H12021 for dry AMD therapy.
Researchers at the Institute of Genetics, TCD, Dublin and the Department of Ophthalmology, McGill University, Montreal have reported significant research results supporting replenishment of the… Read More »Therapeutic implications reported in relation to a unique dominant RPE65 mutation with autosomal dominant retinitis pigmentosa (adRP)
Researchers at the University of Hong Kong have reported that clinicians may need to be aware of special considerations for vulnerable patients with ophthalmic conditions,… Read More »Clinicians consider how COVID19 vaccine rollout may impact outcomes for inflammatory eye disease and autoimmune disorders
Dear EURETINA Members, A very warm welcome to the March 15th, 2021 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to… Read More »March 15th, 2021: “EURETINA-Brief”© Issue No. 231
A systematic review, published in the European Journal of Ophthalmology, has reported a significant number of peer-reviewed studies on ophthalmic-focused COVID-19 articles. A study conducted… Read More »A systematic review has reported ophthalmology-focused publications and findings on COVID-19 pandemic.
A French surgical-robotics company in Montpellier, “AcuSurgical”, has announced a Series A funding of around €5.75 million for an advanced robotic microsurgical platform for the… Read More »“AcuSurgical”, a robotics company for retinal microsurgery based in Montpellier, France, has raised €5.75M funding.
Researchers at the Department of Ophthalmology, at the University of Milan, have published the largest molecular study of Italian patients with RP in the literature. … Read More »The largest molecular study of RP in Italy has reported 591 probands with family history and sporadic cases.
Dear EURETINA Members, A very warm welcome to the February 22nd, 2021 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are… Read More »February 22nd, 2021: “EURETINA-Brief”© Issue No. 230
A US biotechnology company, Advernum Biotechnologies Inc., (NASDAQ:ADVM), has announced the enrolment of a Phase 2 study for the treatment of diabetic macular edema (DME),… Read More »Advernum Biotechnologies Inc., (NASDAQ: ADVM) expects to enrol Phase 2 patients for a treatment for DME using the aflibercept gene.
Research on road driving testing with participants with ocular diseases, compared to aged-matched controls, has shown a significant time delay on a useful hazard perception… Read More »Research on hazard perception testing (HPT) among older drivers with eye disease can be improved with training.